Sandoz Canada and local player JAMP Pharma Corporation have both received approvals from Health Canada for generic versions of Merck & Co’s Januvia (sitagliptin) therapy to improve glycemic control in adult patients with type 2 diabetes mellitus.
At the same time, Sandoz has received approval from the Canadian regulator for a generic to the originator’s sitagliptin-containing fixed-dose combination Janumet (sitagliptin/metformin), which is also indicated as an
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?